# UBX-306

Source: https://onco.cc/drugs/ubx-306/  
OnCo record `ubx-306` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

UBX-306 is an experimental not disclosed from Ubix Therapeutics, at a stage the company does not state for cancer.

## Summary

UBX-306 is a not disclosed (company platform is targeted protein degraders) from Ubix Therapeutics. Undisclosed immuno-oncology programme; the company names no target. The company does not state its stage; it is aimed at cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Listed on the company pipeline; the stage bar is graphical and not readable in page text. No registered trial found on ClinicalTrials.gov. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Last checked: 2026-11-03
- Tags: pipeline
- Code: UBX-306
- Modality: Not disclosed (company platform is targeted protein degraders)
- Mechanism: Undisclosed immuno-oncology programme; the company names no target.

## Sources

- Ubix Therapeutics: ubixtrx.com: https://ubixtrx.com/pipeline

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Ubix Therapeutics](https://onco.cc/companies/ubix-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/ubx-306.json